Cite
HARVARD Citation
Khanna, D. et al. (2018). Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the rheumatic diseases. 77 (2), pp. 212-220. [Online].